Landscapes / Companies
Immunocore Ltd not checked
FollowEvery new trial, moved date and filing, and a Monday email
Drugs
5
in active trials · 9 in all
Trials
6 active
12 since 2021
Drugs5
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Bispecific gp100 peptide-hla-directed CD3 T cell engager |
Approved | Mar 2028Phase 3 trial completes | |||
| Next date | Mar 2028 · Phase 3 trial completes | ||||
| Also tested for | Select Advanced Solid Tumors, Advanced Melanoma | ||||
| Open drug page | |||||
— |
Phase 3 | 16 Oct 2027Phase 3 trial completes | |||
| Next date | 16 Oct 2027 · Phase 3 trial completes | ||||
| Also tested for | Select Advanced Solid Tumors, Advanced Melanoma | ||||
| Open drug page | |||||
— |
Phase 1/2 | 30 Nov 2026soonPhase 1/2 trial completes | |||
| Next date | 30 Nov 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Cancer, HLA-A*02:01-positive | ||||
| Open drug page | |||||
— |
Phase 1 | 30 Sep 2027Phase 1 trial completes | |||
| Next date | 30 Sep 2027 · Phase 1 trial completes | ||||
| Also tested for | PRAME Positive, Cancer and 1 more | ||||
| Open drug page | |||||
— |
Phase 1 | Nov 2030Phase 1 trial completes | |||
| Next date | Nov 2030 · Phase 1 trial completes | ||||
| Also tested for | Type 1 Diabetes, Type 1 Diabetes (T1D) and 1 more | ||||
| Open drug page | |||||
About
- No active trial
- HBV HCC Module, IMC-C103C, IMC-I109V, IMCnyeso
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021